Head-To-Head Comparison: Maravai LifeSciences (NASDAQ:MRVI) versus ANGLE (OTCMKTS:ANPCY)

ANGLE (OTCMKTS:ANPCY) and Maravai LifeSciences (NASDAQ:MRVI) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for ANGLE and Maravai LifeSciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANGLE	0	0	0	0	0.00
Maravai LifeSciences	2	0	2	0	2.00

Maravai LifeSciences has a consensus price target of $6.25, indicating a potential downside of 29.78%. Given Maravai LifeSciences’ stronger consensus rating and higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than ANGLE.

Profitability

This table compares ANGLE and Maravai LifeSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANGLE	N/A	N/A	N/A
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

Insider and Institutional Ownership

50.2% of Maravai LifeSciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ANGLE and Maravai LifeSciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	N/A	N/A	N/A	C($0.48)	-0.14
Maravai LifeSciences	$185.74 million	12.44	-$130.77 million	($0.52)	-17.12

ANGLE has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Summary

Maravai LifeSciences beats ANGLE on 6 of the 11 factors compared between the two stocks.

About ANGLE

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.